Objective: Orlistat is an oral gastrointestinal lipase inhibitor and is indicated for treatment of obesity in combination with a hypocaloric diet. Post-marketing reports of adverse reactions revealed hints for possible drug-induced liver injury which has prompted changes to the product information. Orlistat’s development program, involving over 30,000 patients, did not indicate a hepatic safety issue. Methods: We analyzed liver function test data from randomized clinical trials of orlistat, using i) meta-analysis of published study safety data, ii) time-to-event analysis for individual patients, and iii) a novel and more sensitive method derived from the US Food and Drug Administration’s (FDA) Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH) technique. Over 10,000 subjects were included. Results: The combined odds ratio from a simple summary-level fixed-effects meta-analysis of treatment-emergent abnormalities in serum alanine aminotransferase (ALT) (defined as greater than the upper level of normal for 2 successive measurements) was 1.09 (95% CI 0.93–1.28), and in total bilirubin 1.24 (95% CI 1.03–1.49). Part of the small apparent effect was due to longer exposure to orlistat than to placebo, on average. A patient-level display, adjusting for regression towards the mean, and Kaplan-Meier analysis of changes in ALT and bilirubin, taking account of different exposure, showed no significant difference between orlistat and placebo. This shows that there is no signal for hepatic damage in clinical studies of orlistat. Conclusion: While idiosyncratic liver injury following exposure to orlistat cannot be excluded, it is likely to be extremely rare.

Keywords:
Epidemiology, Obesity management, Pharmacological therapy, Drug toxicity, Meta-analysis
1.
Temple RJ, Himmel MH: Safety of newly approved drugs: implications for prescribing. JAMA 2002;287:2273–2275.
2.
US Food and Drug Administration: Questions and Answers: Orlistat and Severe Liver Injury. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213040.htm.
3.
Zhi J, Mulligan TE, Hauptman JB: Long-term systemic exposure of orlistat a lipase inhibitor and its metabolites in obese people. J Clin Pharmacol 1999;39:41–46.
4.
Lee WM, Senior JR: Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005;33:155–164.
5.
Lee WM: Acute liver failure in the united states. Semin Liver Dis 2003;23:217–226.
6.
Chitturi S, Farrell GC: Etiopathogenesis of non-alcoholic steatohepatitis. Semin Liver Dis 2001;21:27–41.
7.
El-Serag HB, Everhart JE: Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002;122:1822–1828.
8.
Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA: Orlistat for overweight subjects with non-alcoholic steatohepatitis: a randomized prospective trial. Hepatology 2009;49:80–86.
9.
Shapiro MA, Lewis JH: Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007;11:477–505.
10.
Sutton AJ, Cooper NJ, Lambert PC, Jones DR, Abrams KR, Sweeting MJ: Meta-analysis of rare and adverse event data. Expert Rev Pharmacoecon Outcomes Res 2002;2:367–379.
11.
Zimmerman HJ: The spectrum of hepatotoxicity. Perspect Biol Med 1968;12:135–161.
12.
Guo T, Gelperin K, Senior J: A tool to help you decide (detect potentially serious liver injury). 2008. www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ucm076777.pdf.
13.
Cai Z, Christianson M, Stahle L, Keisu M: Reexamining transaminase elevation in Phase I clinical trials: the importance of baseline and change from baseline. Eur J Clin Parmacol 2009;65:1025–1035.
14.
Chuang-Stein C: The regression fallacy. Drug Inform J 1993;27:1213–1220.
15.
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. JAm StatistAssoc 1958;53:457–481.
16.
Lane PW, Nelder JA: Analysis of covariance and standardization as instances of prediction. Biometrics 1980;38:613–621.
17.
Breslow NE, Cain KC: Logistic regression for two-stage case-control data. Biometrika 1998;75:11–20.
18.
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Chichester, John Wiley & Sons Ltd., 2009.
© 2012 S. Karger GmbH, Freiburg
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.